The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. (Q53156735)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 July 2012

Language	Label	Description	Also known as
English	The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.	scientific article published on 17 July 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Roman A Blaheta

9

object named as

Roman A Blaheta

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

author name string

Stefan Vallo

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Jens Mani

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Matthias Stastny

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Jasmina Makarević

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Eva Juengel

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Igor Tsaur

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Georg Bartsch

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Axel Haferkamp

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

publication date

17 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

31

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

265-272

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Therapeutic options in androgen-independent prostate cancer: building on docetaxel

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Phase II study of sunitinib in men with advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Dasatinib: an anti-tumour agent via Src inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Depsipeptide (FK228) inhibits growth of human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Fibroblast growth factors and their receptors in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9851-5

21 January 2018

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/22801803

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

1 reference

https://pubmed.ncbi.nlm.nih.gov/22801803

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9851-5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22801803

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53156735&oldid=2212012281"